You are here: Industry Insights > AstraZeneca

News List

FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer biospace
January 15, 2018
AstraZeneca and Merck today announced that the FDA has approved LYNPARZA® (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm)
AstraZeneca's BYDUREON BCise Injectable Medicine Now Available in the U.S. for Patients With Type-2 biospace
January 11, 2018
AstraZeneca today announced that BYDUREON® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the United States.
AstraZeneca Unloads Four NDAs to ANI Pharmaceuticals in $46.5M Deal biospace
January 02, 2018
ANI Pharmaceuticals, Inc. today announced that it has received $ 45 million in cash from the NDA and AstraZeneca Inc.'s ATACAND®, ATACANDHCT®, ARIMIDEX®, and CASODEX® in the United States
AZ and ICL link to research respiratory diseases pharmatimes
December 25, 2017
AstraZeneca and Imperial College London have announced plans to work together on investigating the scientific mechanisms and underlying drivers of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cance worldpharmanews
December 19, 2017
AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has accepted the Supplemental New Drug Application (sNDA)
AZ’ Tudorza hits study goals in COPD patients with CV risk factors pharmatimes
December 06, 2017
AstraZeneca says top-line results from a post-marketing study show that Tudorza Pressair is effective in reducing chronic obstructive pulmonary disease (COPD) exacerbations in patients with cardiovascular issues.
AstraZeneca’s regulatory submission accepted for Tagrisso pharmaceutical-technology
December 01, 2017
The European Medicines Agency (EMA) has accepted AstraZeneca’s variation to the marketing authorisation application (MAAv) submission for Tagrisso (osimertinib) to treat patients with non-small-cell lung cancer (NSCLC).
AstraZeneca, Chinese FIIF establish joint venture Dizal Pharmaceutical in China pharmaasia
November 30, 2017
Collaboration aims to accelerate local development of innovative medicines for patients in China and builds on AstraZeneca’s strong presence in the country
AstraZeneca and Chinese Future Industry Investment Fund joint to develop new medicines worldpharmanews
November 28, 2017
AstraZeneca today announced the formation of a strategic joint venture with China's Future Industry Investment Fund (FIIF).
AZ’ Fasenra gets US nod for eosinophilic asthma pharmatimes
November 16, 2017
AstraZeneca’s biologic Fasenra has picked up its first global approval in the US as a treatment for severe, eosinophilic asthma, a difficult to treat form of the condition.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page